Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The document serves as a notification of major holdings submitted to the U.S. Securities and Exchange Commission and the UK Financial Conduct Authority (FCA). It details a change in voting rights ownership by a third-party investor, Dodge & Cox.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership thresholds.
Material Changes
The material change reported is an acquisition of voting rights by Dodge & Cox, based in San Francisco, United States. On February 19, 2021, the investor crossed a notifiable threshold, resulting in a total holding of 5.04% of GSK's voting rights. This position comprises:
- Ordinary Shares (GB0009252882): 99,377,874 voting rights (1.98%).
- ADRs (US37733W1053): 154,086,234 voting rights (3.06%).
- Total Voting Rights: 253,464,108 shares.
No financial instruments with similar economic effects or options to acquire additional voting rights were reported in this notification.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document confirms that Dodge & Cox is not controlled by any natural person or legal entity and does not control other undertakings holding an interest in the issuer.
Investor Verification Checklist
- Verify the total voting percentage held by Dodge & Cox (5.04%) against the company's latest shareholder register.
- Confirm the breakdown of holdings between Ordinary Shares and ADRs as disclosed.
- Check for subsequent filings to monitor if the investor crosses higher notification thresholds (e.g., 10%, 15%).
- Note that this filing does not reflect GSK's operational or financial performance for the period.